The boss of the pharmaceutical giant Pfizer, Albert Bourla announced, Monday, January 10, that a version of the COVVI-19 vaccine, adapted to Omicron, will be ready by next March.
“I don’t know if we will need it, I don’t know if, nor how it will be used, but we will be ready. The factory has already started production, ”he said on the American financial channel CNBC.
“We hope to be able to arrive at a product that will protect much better against infections in particular, because protection against hospitalizations and severe cases is quite reasonable with current vaccines if you had the third dose,” explained Albert Bourla.
By the way, the lab had indicated in late November that it had already started working on a new version of the vaccine targeting more specifically omicron.
For his part, Moderna Director of Moderna, Stéphane Bancel, said that his laboratory worked on a recall dose for this fall also aimed at omicron, which should enter “soon” in clinical trial.
